Abstract
Aim:
Several epidemiological studies have suggested that treatment with angiotensin II type 1 receptor blocker provided a risk reduction of developing type 2 diabetes. The aim of this study was to investigate whether and how chronic candesartan treatment can attenuate the deleterious influence of the hyperactive local intra-islet renin-angiotensin system in the diabetes state.
Methods:
Eight-week-old db/db mice were randomized to candesartan 1 mg/kg, candesartan 10 mg/kg, manidipine 10 mg/kg, or placebo via gavage for 6 weeks. Their age-matched nondiabetic littermates db/m mice were treated with placebo and acted as nondiabetic controls. After 6 weeks’ treatment, an intraperitoneal glucose tolerance test, immunohistochemical staining of oxidative stress markers, insulin, CD31, azan staining and an electron microscopy observation were performed.
Results:
Chronic candesartan treatment provided an improvement of glucose tolerance, and greatly rescued islet β-cell mass. Candesartan treatment also notably decreased staining intensity of oxidative stress markers, as well as attenuating intra-islet fibrosis and improving blood supply in the islet. In the electron microscopy observation, candesartan-treated animals exhibited improved granulation and less remarkable endoplasmic reticulum and Golgi bodies; furthermore, candesartan treatment greatly relieved the swelling of mitochondria to nearly normal. Both the benefits of reducing oxidative stress and ultrastructure protection were in a dose-dependent and blood pressure-independent manner.
Conclusion:
After diabetes was initiated, candesartan treatment could not reverse the state of diabetes, but it effectively improved glucose tolerance and protected β-cell function by attenuating oxidative stress, islet fibrosis, sparsity of blood supply and ultrastructure disruption in a dose-dependent and blood pressure-independent manner.
Similar content being viewed by others
Article PDF
References
Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S . Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85–96.
Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR . Pancreatic beta-cells express phagocyte-like Nad (P)H oxidase. Diabetes 2003; 52: 1457–63.
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–86.
Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, et al. Characteristics of 15, 314 hypertensive patients at high coronary risk. The value trial. The Valsartan antihypertensive long-term use evaluation. Blood Press 2001; 10: 83–91.
Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.
Leung PS, Chappell MC . A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 2003; 35: 838–46.
Leung PS, Carlsson PO . Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001; 26: 155–64.
Lau T, Carlsson PO, Leung PS . Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240–8.
Kampf C, Lau T, Olsson R, Leung PS, Carlsson PO . Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. Diabetologia 2005; 48: 1159–67.
Leung PS, Carlsson PO . Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005; 30: 293–8.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM . Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?*. Diabetes 2003; 52: 1–8.
Wu LL, Chiou CC, Chang PY, Wu JT . Urinary 8-Ohdg: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1–9.
Dianzani MU . 4-Hydroxynonenal from pathology to physiology. Mol Aspects Med 2003; 24: 263–72.
Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS . Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005; 25: 65–70.
Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001; 103: 125–32.
Boquist L, Hellman B, Lernmark A, Taljedal IB . Influence of the mutation “diabetes” on insulin release and islet morphology in mice of different genetic backgrounds. J Cell Biol 1974; 62: 77–89.
Like AA, Chick WL . Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets. Diabetologia 1970; 6: 216–42.
Diani AR, Sawada G, Wyse B, Murray FT, Khan M . Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 286: E116–22.
Fernandez-Checa JC, Garcia-Ruiz C, Colell A, Morales A, Mari M, Miranda M, et al. Oxidative stress: role of mitochondria and protection by glutathione. Biofactors 1998; 8: 7–11.
Santos DL, Palmeira CM, Seica R, Dias J, Mesquita J, Moreno AJ, et al. Diabetes and mitochondrial oxidative stress: a study using heart mitochondria from the diabetic Goto-Kakizaki rat. Mol Cell Biochem 2003; 246: 163–70.
Welt K, Weiss J, Martin R, Dettmer D, Hermsdorf T, Asayama K, et al. Ultrastructural, immunohistochemical and biochemical investigations of the rat liver exposed to experimental diabetes and acute hypoxia with and without application of ginkgo extract. Exp Toxicol Pathol 2004; 55: 331–45.
Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M . Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 271–9.
Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M . Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006; 12: 2888–93.
Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME . Improved islet morphology after blockade of the renin-angiotensin system in the Zdf rat. Diabetes 2004; 53: 989–97.
Nakayama M, Inoguchi T, Sonta T, Maeda Y, Sasaki S, Sawada F, et al. Increased expression of Nad(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an At1 receptor antagonist. Biochem Biophys Res Commun 2005; 332: 927–33.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project partly supported by the Japan-China Sasakawa medical fellowship.
Rights and permissions
About this article
Cite this article
Shao, Jq., Iwashita, N., Du, H. et al. Angiotensin II receptor blocker provides pancreatic β-cell protection independent of blood pressure lowering in diabetic db/db mice. Acta Pharmacol Sin 28, 246–257 (2007). https://doi.org/10.1111/j.1745-7254.2007.00492.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00492.x
Keywords
This article is cited by
-
Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade
Kidney International (2008)